Icon of the Instituts for Quality and Efficiency in Health Care

[A19-56] Olaparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V

Last updated 15.10.2019

Project no.:
A19-56

Commission:
Commission awarded on 11.07.2019 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Cancer

Indication:

Women whose advanced BRCA1/2-mutated high-grade epithelial ovarian cancer has responded completely or partially to first-line platinum-based chemotherapy

Result of dossier assessment:

Several hints of greater harm regarding side effects; no informative results regarding overall survival. Added benefit not proven.

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Project no. Title Status
A19-57 Olaparib (breast cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A18-36 Olaparib (ovarian, fallopian tube, peritoneal cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
G15-05 Olaparib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment) Commission completed
A24-88 Olaparib (maintenance in combination with durvalumab; endometrial cancer) – Benefit assessment according to §35a Social Code Book V Commission completed
A22-117 Olaparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A23-03 Olaparib (prostate cancer) - Benefit assessment according to § 35a SGB V Commission completed
A20-115 Olaparib (adenocarcinoma of the pancreas) - Benefit assessment according to §35a Social Code Book V Commission completed
A20-106 Olaparib (prostate cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A20-111 Olaparib (ovarian cancer; first-line maintenance in combination with bevacizumab) - Benefit assessment according to §35a Social Code Book V Commission completed
A23-32 Olaparib (ovarian cancer) – Benefit assessment according to §35a Social Code Book V Commission completed
A22-89 Olaparib (breast cancer, adjuvant) – Benefit assessment according to §35a Social Code Book V Commission completed

Contact

Press contact

+49 221 356850

presse@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page